^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    IGLL5 mutation

    i
    Other names: IGLL5, Immunoglobulin Lambda Like Polypeptide 5, Immunoglobulin Lambda-Like Polypeptide 5, Germline Immunoglobulin Lambda 1, G Lambda-1, Immunoglobulin Light Chain Variable Region EM1-PPS-4-L1-1, Immunoglobin Anti-GranzymeB Light Chain Variable Region, Immunoglobulin Lambda Light Chain Variable Region, Immunoglobulin Lambda-3 Surrogate Light Chain, Anti HBs Antibody Light-Chain Fab Fragment, Immunoglobulin Lambda 1 Light Chain, Immunoglobulin Lambda 2 Light Chain, Immunoglobulin Lambda 3 Light Chain, Omega Light Chain Protein 14.1, VL-MAR, IGLV, IGL
    Entrez ID:
    100423062
    over1year
    Next-generation integrated sequencing identifies poor prognostic factors in patients with MYD88-mutated chronic lymphocytic leukemia in Taiwan. (PubMed, Pathobiology)
    IGLL5, MYD88, and KMT2D mutations were enriched in Taiwanese CLL, and co-occurrence of MYD88 mutations with KMT2D or/and IGLL5 mutations was associated with a poorer prognosis.
    Journal
    |
    MYD88 (MYD88 Innate Immune Signal Transduction Adaptor) • IGH (Immunoglobulin Heavy Locus) • KMT2D (Lysine Methyltransferase 2D) • IGLL5 (Immunoglobulin Lambda Like Polypeptide 5) • DSCAM (DS Cell Adhesion Molecule) • TCHH (Trichohyalin)
    |
    MYD88 mutation • KMT2D mutation • MYD88 L265P • IGLL5 mutation
    almost2years
    Dynamic monitoring of circulating tumor DNA reveals outcomes and genomic alterations in patients with relapsed or refractory large B-cell lymphoma undergoing CAR T-cell therapy. (PubMed, J Immunother Cancer)
    Our study highlights that dynamic ctDNA monitoring during CAR T-cell therapy can be a promising non-invasive method for early predicting treatment response and survival outcomes. Additionally, the ctDNA mutational profile provides novel insights into the mechanisms of tumor-intrinsic resistance to CAR19 T-cell therapy.
    Journal • CAR T-Cell Therapy • Circulating tumor DNA
    |
    TP53 (Tumor protein P53) • CD79B (CD79b Molecule) • GNA13 (G Protein Subunit Alpha 13) • P2RY8 (P2Y Receptor Family Member 8) • PIM1 (Pim-1 Proto-Oncogene) • IGLL5 (Immunoglobulin Lambda Like Polypeptide 5)
    |
    TP53 mutation • IGLL5 mutation
    over2years
    Whole Genome Classification of Pre-Malignant B-Cells Disorder of the Oxplored Study (ASH 2023)
    The comprehensive characterisation of genomic events that determine progression to malignancy are essential to understand the mechanisms of disease progression. Our study opens new horizons towards identifying individuals at higher risk and might pinpoint to individuals who need early intervention with curative intent. Therefore, we propose to analyse newly generated whole-genome sequencing (WGS) data to establish genomic subgroups in early CLL / pre-malignancy stages.
    Tumor mutational burden
    |
    TMB (Tumor Mutational Burden) • NOTCH1 (Notch 1) • MYD88 (MYD88 Innate Immune Signal Transduction Adaptor) • SF3B1 (Splicing Factor 3b Subunit 1) • BCL6 (B-cell CLL/lymphoma 6) • IGH (Immunoglobulin Heavy Locus) • CREBBP (CREB binding protein) • BIRC3 (Baculoviral IAP repeat containing 3) • PAX5 (Paired Box 5) • IGLL5 (Immunoglobulin Lambda Like Polypeptide 5)
    |
    MYD88 mutation • IGH mutation • IGLL5 mutation • TS 12